Portola Pharmaceuticals   Print Page    Close Window

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
02/21/17Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 28
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter and year ended December 31, 2016, and provide a general business overview on Tuesday, February 28, 2017, at 4:30 p.m. ET (1:30 p.m. PT). Conference Call Details The live conference call on Tuesday, February 28, 2017, at 4:30 p.m. Eastern Time, can be accessed by ph... 
Printer Friendly Version
02/08/17FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting
PDUFA Date of June 24, 2017 Under Priority Review SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) has informed the Company, as part of its mid-cycle review, that it does not plan to hold an Advisory Committee meeting for Portola’s New Drug Application (NDA) for betrixaban. Betrixaban is an oral, once-daily Factor Xa inhib... 
Printer Friendly Version
02/03/17Portola Pharmaceuticals Signs $150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanet Alfa
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it has signed a $150 million royalty agreement with HealthCare Royalty Partners (HCR). Under the terms of the agreement, Portola received $50 million at closing and may receive an additional $100 million upon U.S. Food and Drug Administration (FDA) approval of AndexXaTM (andexanet alfa) in exchange for a tiered, mid-single-digit royalty based on worldwide sales of th... 
Printer Friendly Version
01/03/17Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it will host an investor webcast to review recent achievements and corporate and product milestones over the next year. The webcast, which will take place on Tuesday, January 10, at 7 a.m. Pacific Time (10 a.m. Eastern Time), will coincide with the 35th Annual J.P. Morgan Healthcare Conference in San Francisco. During the investor event, Portola’s senior managemen... 
Printer Friendly Version